Home
Series of Journals
Literature
Latest literature
Popular literature
About us
Intro
Organizational structure
Editor in Chief
Copyright
Contact us
The title
The title
The keywords
The author
Wuhan University
Zhongnan Hospital of Wuhan University
Center for Evidence-Based and Translational Medicine of Wuhan University
Home
Results
The title
The title
The keywords
The author
A total of
7
result was found. Results that relate to
Markov model
Cost-utility analysis of sacubitril/valsartan, dapagliflozin and empagliflozin in heart failure with reduced ejection fraction
Published on
Chinese Journal of Pharmacoepidemiology
2023,32(8):878-885.
577 times
242 times
Dan-Dan LU
Sheng-Xiang WANG
Shan LU
Dan PAN
Li-Yuan SHI
Fei-Chuang Jing2
Heart failure with reduced ejection fraction
Sacubitril/valsartan
Dapagliflozin
Empagliflozin
Markov model
Cost-utility analysis
Details
Cost-effectiveness analysis of abemaciclib plus fulvestrant in the second-line treatment for HR﹢/HER2﹣ advanced breast cancer
Published on
Chinese Journal of Pharmacoepidemiology
2023,32(11):1259-1266.
494 times
317 times
Xi ZHAO
Xi YAN
Ning LI
Chun-Xia HOU
Abemaciclib
Fulvestrant
Hormone receptor-positive breast cancer
Markov model
Cost-effectiveness analysis
Details
Cost-utility analysis of azacitidine versus decitabine in the treatment of myelodysplastic syndrome
Published on
Chinese Journal of Pharmacoepidemiology
2023,32(12):1371-1379.
380 times
178 times
La-Ji DANZENG
Yong-Gong YANG
Si-Liang WANG
Meng-Ying LIU
Azacitidine
Decitabine
Myelodysplastic syndrome
Markov model
Cost-utility analysis
Pharmacoeconomics
Details
Pharmacoeconomic evaluation of different doses of rivaroxaban for the prevention of thrombosis in patients with nonvalvular atrial fibrillation
Published on
China Pharmacist
2023,36(11):233-240.
334 times
244 times
Wei LUO
Xue-Ying PENG
Dong YANG
Xin-Mei WU
Nonvalvular atrial fibrillation
Rivaroxaban
Dose selection
Markov model
Cost-utility analysis
Details
Cost-effectiveness analysis of enzalutamide in the treatment of metastatic prostate cancer
Published on
Chinese Journal of Pharmacoepidemiology
2024,33(3):269-276.
405 times
201 times
YANG Lei
WANG Fengling
HUANG Ling
LI Yan
ZHENG Hanrui
ZHENG Lingli
CHEN Li
Enzalutamide
Metastatic prostate cancer
Markov model
Cost-effectiveness analysis
Details
Pharmacoeconomic evaluation of glucagon-like peptide-1 receptor agonist combined with metformin in the treatment of type 2 diabetes mellitus
Published on
Chinese Journal of Pharmacoepidemiology
2024,33(4):388-401.
257 times
491 times
YU Tian
LIU Shaohua
WEI Anhua
GUO Jieru
ZHANG Chengliang
LIU Dong
LIU Zhelong
Glucagon-like peptide-1 receptor agonist
Metformin
Type 2 diabetes mellitus
Cost-utility
Markov model
Pharmacoeconomics
Details
Pharmacoeconomic evaluation of aflibercept versus conbercept for the treatment of wet age-related macular degeneration
Published on
China Pharmacist
2024,27(4):655-662.
90 times
38 times
LIU Dan
ZHANG Bochao
ZHANG Jing
WANG Juan
YUAN Yi
GUI Lin
CHEN Li
Wet age-related macular degeneration
Aflibercept
Conbercept
Markov model
Pharmacoeconomic analysis
Details